---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077061"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T14:07:59.328375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share

## Summary
- Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.
- Underwriters have 30-day option to buy up to 2,250,000 additional shares (full exercise net ~$82.4M).
- Proceeds to advance clinical pipeline including BDTX-1535 for non-small cell lung cancer and for working capital.
- Underwriting agreement with Piper Sandler & Co.; officers/directors subject to 60-day lock-up.
- Offering expected to close July 5, 2023.

## SEC filing metadata
- accession: 0001104659-23-077061
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/0001104659-23-077061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/tm2320300d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077061
- JSON: https://secwatch.observer/filing/0001104659-23-077061.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077061.txt

## Key facts
- Material Agreements
  Black Diamond Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters valued at approximately $71.6 million (effective 2023-06-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co., as representative of the several underwriters
  - Value: approximately $71.6 million
  - Effective: 2023-06-29
  source text: On June 29, 2023, Black Diamond Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 15,000,000 shares (the “Shares”) of common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/0001104659-23-077061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.